EBSAM
GBT

Eubel Brady & Suttman Asset Management’s Global Blood Therapeutics, Inc. GBT Stock Holding History

Eubel Brady & Suttman Asset Management’s Portfolio GBT Stock Details GBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-31,796
Closed -$32K – 82
2019
Q4 		$32K Buy
+31,796
New +$1.88M 0.01% 75

Other funds holding GBT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Eubel Brady & Suttman Asset Management's GBT Position: Q1 2020 in Review

Eubel Brady & Suttman Asset Management sold out of Global Blood Therapeutics, Inc. (GBT) in Q1 2020, closing a stake of 31,796 shares — an estimated $32K sold.

Eubel Brady & Suttman Asset Management first reported a position in GBT in Q4 2019 and held it in 1 quarter. The position peaked at $32K in Q4 2019. 220 funds tracked by Wall St. Rank hold GBT as of Q1 2020.

  • Eubel Brady & Suttman Asset Management reported no remaining Global Blood Therapeutics, Inc. position as of Q1 2020 after selling out during the quarter.
  • Eubel Brady & Suttman Asset Management sold 31,796 Global Blood Therapeutics, Inc. shares in Q1 2020, an estimated $32K.
  • Eubel Brady & Suttman Asset Management first reported a position in Global Blood Therapeutics, Inc. in Q4 2019 and held it in 1 quarter.
  • Eubel Brady & Suttman Asset Management's Global Blood Therapeutics, Inc. position peaked at $32K in Q4 2019.
  • 220 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q1 2020.

Based on Eubel Brady & Suttman Asset Management's 13F filing for Q1 2020, filed 13 May 2020.